Mitochondrial antiviral signaling protein, usually called MAVS, is an immune-signaling protein encoded by the MAVS gene. It sits mainly on the outer mitochondrial membrane and helps cells respond to viral RNA by activating pathways that produce type I interferons and inflammatory signals. MAVS is important biology, but it is not itself a consumer treatment.
Not sure where to start? Take the 3-min clinical quiz.
See if you qualify →What is mitochondrial antiviral signaling protein?
Mitochondrial antiviral signaling protein is usually shortened to MAVS. It is a human protein that helps the innate immune system respond when a cell detects viral genetic material, especially viral RNA 1.
The name MAVS comes from its role and location: mitochondrial, antiviral, and signaling. The human MAVS gene is annotated by NCBI Gene as involved in activation of innate immune response, antiviral innate immune response, defense response to virus, cellular response to interferon-beta, and negative regulation of viral genome replication 1.
What MAVS stands for
MAVS stands for mitochondrial antiviral signaling protein. In simple terms, it is a relay station. It helps pass the message from viral-RNA sensors to the cell’s antiviral gene programs 2.
Other names: IPS-1, VISA, and Cardif
MAVS was identified by several research groups and has been called IPS-1, VISA, and Cardif in the scientific literature 3, 4, 5. These names refer to the same core adaptor protein in the RIG-I-like receptor pathway.
Why MAVS is discussed in mitochondrial and immune research
Researchers discuss MAVS because it connects mitochondria with antiviral innate immunity. That makes it interesting for studies of immune homeostasis, inflammation, kidney disease, cardiovascular disease, cancer biology, and mitochondrial signaling—but those research links are not the same as proven patient benefits or lifespan extension 2.
Quick facts about MAVS
MAVS is best understood as an immune adaptor, not a hormone, supplement, peptide, or drug target used in routine care. The core facts are about its gene, location, partners, and signaling role.
| Feature | Plain-English answer | Evidence type |
|---|---|---|
| Gene | MAVS, a human gene listed by NCBI Gene | Official gene annotation 1 |
| Main protein location | Mostly the outer mitochondrial membrane | Mechanistic and review evidence 2, 6 |
| Main role | Antiviral innate immune signaling after viral RNA is detected | Human gene annotation and mechanistic studies 1, 6 |
| Key upstream partners | RIG-I and MDA5, also called RIG-I-like receptors | Primary discovery and pathway studies 6, 7 |
| Longevity caution | MAVS biology does not prove a way to extend human lifespan | Research-stage inference, not human lifespan trial evidence 2 |
Where is MAVS found in the cell?
MAVS is found mainly on the outer mitochondrial membrane, with signaling also discussed at mitochondria-associated membranes. This location lets viral-RNA detection connect quickly to immune signaling hubs 2.
Outer mitochondrial membrane
The outer mitochondrial membrane is the outside boundary of the mitochondrion. MAVS is anchored there by a C-terminal transmembrane domain, which is important for its signaling function 2, 6.
Mitochondria-associated membranes
Mitochondria-associated membranes are contact zones between mitochondria and the endoplasmic reticulum. Reviews describe MAVS-related signaling at these membrane contact sites, which may help coordinate immune and stress responses inside the cell 2.
Why location matters for immune signaling
Location matters because signaling proteins must meet in the right place. When RIG-I-like receptors detect viral RNA, they interact with MAVS at mitochondrial signaling sites, helping form a platform that turns on antiviral genes 6, 7.
What does MAVS do during a viral infection?
MAVS helps a cell sound the alarm during RNA virus infection. It receives signals from viral-RNA sensors and helps activate type I interferons, NF-kappaB signaling, and inflammatory cytokines 1, 2.
How viral RNA is sensed by RIG-I-like receptors
RIG-I and MDA5 are RIG-I-like receptors. They patrol the cell interior for viral RNA patterns that should not be there, then trigger downstream signaling through MAVS 7, 8.
How RIG-I and MDA5 signal through MAVS
After viral RNA is detected, RIG-I or MDA5 changes shape and uses CARD domains to interact with the CARD domain on MAVS. This helps MAVS assemble a larger signaling platform on mitochondrial membranes 6, 7.
How MAVS helps activate type I interferon pathways
MAVS signaling helps activate transcription factors such as IRF3 and IRF7. These factors support production of type I interferons, including interferon-alpha and interferon-beta, which help nearby cells enter an antiviral state 1, 7.
How MAVS connects to NF-kappaB and inflammatory cytokines
NCBI Gene annotates MAVS as involved in positive regulation of canonical NF-kappaB signaling, tumor necrosis factor production, and chemokine production 1. This is useful during infection, but excess innate immune signaling can also contribute to inflammatory disease mechanisms, which is why MAVS is not something to try to alter on your own 2.
What is the MAVS signaling pathway in simple terms?
The MAVS pathway is a four-step alarm system. A cell detects viral RNA, passes that message through RIG-I or MDA5 to MAVS, builds a signaling platform, and switches on immune genes 6, 7.
- 1Step 1: a cell detects viral RNA. RIG-I-like receptors recognize viral RNA patterns in the cytoplasm 7.
- 2Step 2: RIG-I or MDA5 changes shape and binds MAVS. This lets the sensor pass the signal to the mitochondrial adaptor 6.
- 3Step 3: MAVS forms a signaling platform. MAVS helps recruit downstream proteins that organize the antiviral response 2.
- 4Step 4: immune genes are switched on. IRF3, IRF7, and NF-kappaB pathways help drive interferons and cytokines 1, 2.
What is the structure of the MAVS protein?
The MAVS protein has 3 main regions often described in research: an N-terminal CARD domain, a central proline-rich region, and a C-terminal transmembrane domain. These parts help it receive signals, recruit partners, and stay anchored to membranes 2, 6.
CARD domain
The CARD domain is the signal-matching region. It helps MAVS interact with CARD domains on RIG-I-like receptors after viral RNA sensing 6, 7.
Proline-rich region
The proline-rich region sits in the middle of MAVS. Reviews describe it as a region that can help recruit signaling partners, though different experimental systems may assign different levels of importance to this segment 2.
Transmembrane domain
The transmembrane domain is at the C-terminal end of MAVS. In fish cell experiments, deletion work showed the N-terminal CARD-like region and C-terminal transmembrane region were required for MAVS signaling function in that preclinical model 6.
Why the transmembrane domain anchors MAVS to mitochondria
A transmembrane domain acts like an anchor in a membrane. For MAVS, that anchor places the protein at mitochondrial signaling sites, where it can organize antiviral innate immune signaling 2, 6.
Which proteins work with MAVS?
MAVS works with viral sensors, adaptor proteins, transcription factors, and inflammatory complexes. The best-known partners include RIG-I, MDA5, TRAF proteins, IRF3, IRF7, NF-kappaB, and the NLRP3 inflammasome 1, 2.
- RIG-I: a cytosolic viral-RNA sensor that can signal through MAVS after recognizing certain viral RNA patterns 7.
- MDA5: another RIG-I-like receptor that detects viral RNA and uses MAVS for downstream signaling 8.
- TRAF proteins: signaling adaptors described in MAVS pathway reviews as part of downstream immune activation 2.
- IRF3 and IRF7: transcription factors that support type I interferon production after MAVS pathway activation 1, 7.
- NF-kappaB: a major inflammation-related transcription pathway positively regulated by MAVS in gene annotations and pathway studies 1.
- NLRP3 inflammasome: an inflammatory complex linked to MAVS in gene annotation and review literature, especially in disease-mechanism research 1, 2.
Can viruses block MAVS signaling?
Some viruses can interfere with MAVS signaling as part of immune evasion. This is one reason MAVS is studied in virology and host-defense research 2, 9.
Why viruses evolve immune-evasion strategies
Viruses rely on host cells to replicate. If a cell’s antiviral alarm turns on quickly, viral genome replication may be limited; NCBI Gene annotates MAVS as involved in negative regulation of viral genome replication 1.
Examples of viral interference described in research
Hepatitis C virus research helped show that the viral NS3/4A protease can disrupt MAVS/Cardif signaling, weakening interferon-beta pathway activation in experimental systems 9. This is mechanistic evidence about viral immune evasion, not a home treatment strategy.
Why this does not mean people should try to alter MAVS on their own
MAVS sits in a powerful immune pathway. Turning innate immune signaling up or down could carry risks, including too little antiviral defense or too much inflammation, so MAVS is not a do-it-yourself supplement target 2.
Is MAVS related to longevity or mitochondrial health?
MAVS is related to mitochondrial immune signaling, not proven human lifespan extension. It is reasonable for longevity researchers to study MAVS because chronic inflammation and mitochondrial stress are important aging topics, but MAVS data should not be overstated 2.
How MAVS links mitochondria and immune signaling
MAVS sits at a boundary between mitochondria and immunity. It shows that mitochondria are not only energy organelles; they also help organize stress and immune signals 2, 6.
What human evidence can and cannot say
Human databases and reviews support that MAVS is a real human gene and immune-signaling protein 1, 2. They do not show that raising or lowering MAVS activity in people extends lifespan, improves healthspan, or works as a longevity treatment.
What is preclinical, cell, or animal evidence
Some MAVS work is preclinical. For example, a fish cell study found that overexpressing MAVS induced interferon and interferon-stimulated genes and protected cells against viral infection, with reported 1,000-fold and 10,000-fold decreases in DNA and RNA virus replication in that model 6. That kind of cell evidence helps explain biology, but it does not prove the same result in humans.
Why immune biomarkers do not prove longer human lifespan
Interferons, cytokines, and inflammasome markers are signals, not direct proof of living longer. In longevity research, a biomarker can be useful and still fail to predict a meaningful human outcome; MAVS research should be read with that caution 2.
Is MAVS a treatment target or supplement target?
MAVS is a research target, not a standard consumer therapy. There is no routine MAVS supplement, peptide, or Chia treatment intended to increase MAVS activity.
MAVS is a research target, not a standard consumer therapy
Scientists study MAVS because it sits near important antiviral and inflammatory pathways. But a pathway being important does not mean people should try to manipulate it outside clinical care 2.
Why changing innate immune signaling can carry risk
Innate immune signaling needs balance. Too little signaling can impair host defense, while too much signaling can contribute to inflammation; MAVS has been linked in reviews to inflammatory disease mechanisms and NLRP3 inflammasome activity 1, 2.
When to talk with a clinician about immune or viral-infection concerns
If you have frequent infections, prolonged fever, immune disease, kidney disease, heart disease, cancer, or autoimmune symptoms, talk with a licensed clinician. MAVS biology is not a substitute for diagnosis, testing, vaccination guidance, or treatment decisions.
How does Chia approach topics like MAVS and longevity research?
At Chia, MAVS is education-only. We cover mitochondrial and longevity science to help patients understand the difference between promising biology, early research, and treatments that require clinician review.
MAVS is not a treatment we offer, and we do not present it as a supplement or peptide protocol. When Chia does provide care for treatments in our catalog, the process is 100% online: a short health questionnaire, review by a licensed US provider, prescribing only when clinically appropriate, and home delivery from state-licensed 503A compounding pharmacies.
That distinction matters. Longevity research can be exciting, but a gene pathway is not the same thing as a safe, evidence-based personal plan. Our role is to help patients ask better questions and get clinician-guided care when a treatment is appropriate.
FAQ
Mitochondrial antiviral signaling protein, or MAVS, helps cells respond to viral RNA. It receives signals from viral-RNA sensors such as RIG-I and MDA5 and helps activate interferon and inflammatory pathways.
MAVS acts as an adaptor protein in innate immunity. It helps connect viral detection inside the cell to immune gene programs that can limit viral replication and alert nearby cells.
Type I interferons, such as interferon-alpha and interferon-beta, help neighboring cells enter an antiviral state. MAVS helps activate pathways that support production of these interferons after viral RNA is detected.
Yes. MAVS is a mitochondrial-associated protein, mainly located on the outer mitochondrial membrane. It is also discussed at mitochondria-associated membrane signaling sites.
Examples include MAVS, which helps with antiviral signaling; TOM complex proteins, which help import proteins into mitochondria; and respiratory-chain proteins, which help produce cellular energy.
No. MAVS shows that mitochondria help coordinate immune signaling, but it does not prove that mitochondria control aging or that changing MAVS activity extends human lifespan.
There is no standard consumer supplement or peptide protocol to increase MAVS. MAVS is a research target, not a Chia treatment. If you have immune or infection concerns, speak with a licensed clinician.
References
- 1.National Center for Biotechnology Information. MAVS mitochondrial antiviral signaling protein [Homo sapiens (human)]. NCBI Gene, accessed 2026.
- 2.Zhang J, et al. Mitochondrial antiviral signaling protein: a potential therapeutic target in renal disease. Frontiers in Immunology, 2023.
- 3.Kawai T, Takahashi K, Sato S, et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nature Immunology, 2005.
- 4.Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Molecular Cell, 2005.
- 5.Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature, 2005.
- 6.Biacchesi S, LeBerre M, Lamoureux A, et al. Mitochondrial antiviral signaling protein plays a major role in induction of the fish innate immune response against RNA and DNA viruses. Journal of Virology, 2009.
- 7.Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF3. Cell, 2005.
- 8.Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nature Immunology, 2004.
- 9.Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proceedings of the National Academy of Sciences of the United States of America, 2005.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
Find what fits your body and your goals.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
